Each 5% increase in CMR-derived left atrioventricular coupling index predicted higher all-cause mortality (HR 1.06; 95% CI 1.01-1.11; p=0.016) in patients with reduced ejection fraction.
Cohort (n=2,170)
Yes
Does CMR-derived left atrioventricular coupling index (LACI) predict all-cause mortality and heart failure in patients with reduced LVEF?
CMR-derived LACI (≥21%) independently predicts all-cause mortality and heart failure in patients with reduced LVEF, providing incremental prognostic value beyond LVEF and late gadolinium enhancement.
Effect estimate: HR 1.06 (95% CI 1.01-1.11)
p-value: p=0.016
BACKGROUND: The left atrioventricular coupling index (LACI) has emerged as a potential prognostic marker in several clinical settings. This study evaluated the prognostic value of cardiac magnetic resonance (CMR)-derived LACI in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). METHODS: Patients from the multicenter DERIVATE registry with LVEF <50% who underwent CMR were included. LACI was calculated as the ratio between left atrial and left ventricular end-diastolic volumes. Univariable and multivariable Cox regression models estimated hazard ratios (HR) with 95% confidence intervals (CI) for predicting all-cause mortality (ACM), ACM or HF, and HF alone (competing-risk analysis). Time-dependent receiver operating characteristic analysis identified optimal cutoffs for 3-year outcomes. RESULTS: A total of 2170 patients were included (mean age 59.8±13.9 years; 24.7% women; mean LVEF 31.6±11.3%). Median follow-up was 1016 days (580-1609). Median LACI was 19.4% (13.3-28.8). During follow-up, ACM occurred in 191 patients (8.8%), ACM or HF in 565 (26.0%), and HF in 442 (20.4%). After adjustment for clinical and CMR parameters, including LVEF and late gadolinium enhancement (LGE), each 5% increase in LACI was associated with higher risk of ACM (HR 1.06, 95% CI 1.01-1.11; p=0.016), ACM or HF (HR 1.09, 95% CI 1.06-1.12; p<0.001), and HF (HR 1.09, 95% CI 1.05-1.12; p<0.001). The optimal cutoff for ACM was LACI ≥21% (AUC 0.617, 95% CI 0.561-0.673), identifying patients at higher risk of ACM, ACM or HF, and HF (log-rank p<0.001 for all). CONCLUSIONS: CMR-derived LACI independently predicts ACM and HF in patients with reduced LVEF and provides incremental prognostic value beyond LVEF and LGE. A cutoff of ≥21% identifies higher-risk patients and may support clinical risk stratification.
Guglielmo et al. (Tue,) conducted a cohort in Heart failure with reduced left ventricular ejection fraction (n=2,170). Left atrioventricular coupling index (LACI) was evaluated on All-cause mortality (ACM) (HR 1.06, 95% CI 1.01-1.11, p=0.016). Each 5% increase in CMR-derived left atrioventricular coupling index predicted higher all-cause mortality (HR 1.06; 95% CI 1.01-1.11; p=0.016) in patients with reduced ejection fraction.